- BIIB3-Rx is the third drug that Isis is developing with Biogen Idec. The drug is designed to inhibit an undisclosed target to treat a neurodegenerative disease.
- Isis has now initiated clinical studies, which based on the deal between the two companies, has triggered a $10 million milestone payment. Isis is eligible to receive as much as $215 million in additional milestone payments.
- Biogen has the option to exclusively license BIIB3-Rx, and Isis is eligible to receive royalties.
Not all development partnerships are productive, but the ongoing partnership between Isis and Biogen has yielded three candidates that were ripe for development and have moved into the clinical trial stage. Throughout the process, both partners have played an active role in moving the candidates through the various phases of preclinical and now clinical development, while maintaining open communications---and on the part of Biogen, a willingness to provide additional resources and expertise as needed. Clearly, a winning combination.